Patents Assigned to Flamel Technologies
-
Publication number: 20160095317Abstract: The present invention provides guanidine compounds and salts thereof that may be useful, for example, in the preparation of herbicidal compositions. The compounds may be used, for example, to prepare N-phosphonomethylglycine guanidine salts having improved herbicidal efficacy over glyphosate alone.Type: ApplicationFiled: December 11, 2015Publication date: April 7, 2016Applicants: Monsanto Technology LLC, Flamel TechnologiesInventors: Ronald J. Brinker, Olivier Soula, Alain Lemercier
-
Patent number: 9233993Abstract: The present invention provides N-phosphonomethylglycine guanidine salts. The N-phosphonomethylglycine guanidine salts have improved herbicidal efficacy over glyphosate alone. The present invention also provides guanidine compounds and salts thereof.Type: GrantFiled: June 24, 2010Date of Patent: January 12, 2016Assignees: Monsanto Technology LLC, Flamel TechnologiesInventors: Ronald J. Brinker, Olivier Soula, Alain Lemercier
-
Patent number: 9023400Abstract: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.Type: GrantFiled: May 24, 2007Date of Patent: May 5, 2015Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas
-
Patent number: 8895063Abstract: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.Type: GrantFiled: January 10, 2007Date of Patent: November 25, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas, Gérard Soula, Rémi Soula
-
Patent number: 8821935Abstract: The present invention is directed to microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents. Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (PI) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry matter of their total weight, and its components P1, P2, PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%; dry matter weight fraction of PL/P1+P2 ranging between 15 and 60%; dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%.Type: GrantFiled: October 20, 2006Date of Patent: September 2, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Catherine Castan, Rémi Meyruiex, Gérard Soula
-
Patent number: 8734850Abstract: The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.Type: GrantFiled: November 24, 2004Date of Patent: May 27, 2014Assignee: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula
-
Publication number: 20140105993Abstract: The present invention relates to novel microparticles formed of amphiphilic polyamino acids which transport active principle(s), AP(s), in particular protein and peptide active principle(s), and to novel modified-release pharmaceutical formulations comprising said AP microparticles. Microparticles of amphiphilic polyamino acid (PO) may include at least one AP (associated noncovalently) which spontaneously form a colloidal suspension of nanoparticles in water, at pH 7.0, under isotonic conditions. The microparticles may be obtained by atomization of a solution or colloidal suspension of PO comprising at least one AP, may have a size of between 0.5 and 100 microns, and may be dispersible in colloidal suspension.Type: ApplicationFiled: November 21, 2013Publication date: April 17, 2014Applicant: Flamel Technologies, S.A.Inventors: Alain Constancis, You-Ping Chan
-
Patent number: 8679540Abstract: The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles, and to the applications, especially therapeutic applications, of these formulations. Formulations may include an aqueous colloidal suspension of low viscosity based on micrometric particles of a water-soluble, biodegradable, amphiphilic polymer carrying hydrophobic groups and ionizable hydrophilic groups that are at least partially ionized, said particles being capable of associating spontaneously and non-covalently with an active principle, at pH=7.0, under isotonic conditions. This suspension contains multivalent ions of opposite polarity to that of the hydrophilic groups, the ratio r, defined by the formula r=n×([IM]/[GI]), where n is the valency of said multivalent ions, [IM] is the molar concentration of multivalent ions, [GI] is the molar concentration of ionizable groups GI, being between 0.3 and 10.Type: GrantFiled: June 11, 2007Date of Patent: March 25, 2014Assignee: Flamel TechnologiesInventors: Cécile Bonnet-Gonnet, David Chognot, Olivier Soula, Alain Constancis
-
Publication number: 20140072644Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: FLAMEL TECHNOLOGIESInventors: Florence Guimberteau, Frederic Dargelas
-
Patent number: 8652523Abstract: The invention concerns microcapsules with prolonged release of active principles with low solubility, consisting of a core containing the active principle and coated with a polymer layer which controls the release of the active principle. The aim is that said oral microcapsules containing hardly soluble active principles, should have a coating film of sufficient thickness to ensure controlled permeability and should be adapted to industrial reproduction. This is achieved by the inventive microcapsules of mean diameter less than 1000 microns, and whereof the coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA).Type: GrantFiled: July 28, 2003Date of Patent: February 18, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Catherine Castan, Rémi Meyrueix
-
Patent number: 8652529Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle they contain. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the active principle it comprises is contained in coated microparticles for modified release of the active principle, and in that the coated microparticles have a coating layer which assures modified release of the active principle and simultaneously imparts crushing resistance to the coated microparticles so as to avoid misuse.Type: GrantFiled: May 24, 2006Date of Patent: February 18, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frédéric Dargelas
-
Patent number: 8507003Abstract: A multi(micro)particulate tablet is provided comprising microparticles which comprise a mechanically non-deformable core of active principle (AP). The tablet is formed from reservoir microcapsules with prolonged release of the AP, which are each made up of a non-deformable core comprising AP and covered with at least one film coating controlling release of the AP in vivo. The microcapsules have a particle size of between 50 and 1000 microns and are coated with at least one outer overcoating envelope comprising at least one deformable organic constituent having a melting point of between 40° C. and 120° C. The envelope allows the prolonged release of the AP in vivo without modification of the release profile when the microcapsules are compressed to form a tablet, even for microparticles not specifically formulated for compression.Type: GrantFiled: March 14, 2003Date of Patent: August 13, 2013Assignee: Flamel TechnologiesInventors: Rafaël Jorda, Pierre Autant
-
Patent number: 8481019Abstract: The present invention relates to novel particles comprising polyelectrolyte polymers which are transporters of active principle (AP), in particular protein and peptide active principle, and to novel modified-release pharmaceutical formulations comprising said AP microparticles. These novel particles loaded with AP release the AP over a prolonged period of time of several days, or even several weeks.Type: GrantFiled: May 5, 2008Date of Patent: July 9, 2013Assignee: Flamel TechnologiesInventors: Cecile Bonnet-Gonnet, Frédéric Checot, You-Ping Chan, Olivier Breyne
-
Patent number: 8445023Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.Type: GrantFiled: December 15, 2009Date of Patent: May 21, 2013Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20120308614Abstract: The present invention relates to a novel aqueous liquid pharmaceutical composition for the controlled release of buprenorphine or of an analogue of buprenorphine, comprising at least one prodrug with low aqueous solubility of said buprenorphine or analogue of buprenorphine, and at least one polymer having a linear backbone chosen from the polyglutamates, polyaspartates, poly(meth)acrylates and polysaccharides, to which one or more hydrophobic groups are grafted.Type: ApplicationFiled: May 30, 2012Publication date: December 6, 2012Applicant: Flamel TechnologiesInventors: Aline Moulin, You-Ping Chan
-
Publication number: 20120294832Abstract: The present invention relates to a novel solid composition, useful for treating hepatitis, in particular hepatitis C, comprising at least one interferon alpha and at least one grafted poly(glutamic acid) having an average molar mass ranging from 26,000 to 40,000 g/mol, preferably approximately 33,000 g/mol and carrying grafts of alpha-tocopherol at an average molar grafting rate ranging from 4.5 to 5.5%, preferably approximately 5%, the interferon alpha and said grafted poly(glutamic acid) being present in a grafted poly(glutamic acid)/interferon alpha weight ratio ranging from 21 to 125. It also relates to the use of such a solid composition for the preparation of a liquid composition by the addition of an aqueous liquid.Type: ApplicationFiled: May 16, 2012Publication date: November 22, 2012Applicant: Flamel TechnologiesInventors: Gauthier Pouliquen, You-Ping Chan, Rémi Meyrueix, David Chognot, Roger Kravtzoff
-
Patent number: 8293255Abstract: The invention relates to novel biodegradable materials based on modified polyamino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant protective compositions which are based on said polyamino acids. The aim of said invention is to provide a novel polymer raw material usable for vectoring the AS and capable to optimally meet all specification in this area: biocompatibility, biodegradability, ability to become easily associated with many active substances or to solubilize them and to release said active substances in vivo. The aim is attained to 30 carbon atoms. Said polyglutamates modified by histidine derivatives are soluble with pH lower than 5 and are easily and economically convertible into active substance vectorization particles which are able to form stable aqueous colloidal suspensions. On the contrary, said modified polyglutamates are insoluble in water with a physiological pH (7.Type: GrantFiled: October 31, 2006Date of Patent: October 23, 2012Assignee: Flamel TechnologiesInventors: Olivier Soula, Rémi Soula, Olivier Breyne
-
Patent number: 8236353Abstract: The present invention relates to pharmaceutical formulations for the release of an active principle (AP) over a sustained period of time. The invention relates to a liquid formulation comprising at least one active principle (AP) and an aqueous suspension based on colloidal particles of a polymer (PO), wherein said formulation satisfies the following four conditions: (a) the PO is a polyamino acid comprising glutamic residues, wherein some glutamic residues each carry a pendant cationic group (CG), said CG being identical or different from one another, and other glutamic residues each carry a pendent hydrophobic group (GH), said GH being identical or different from one another, (b) the pHf value of the pH of said formulation is between 3.0 and 6.5; (c) at the pHf value, the PO forms a colloidal solution which associates spontaneously and noncovalently with the AP; (d) 1 ml of said formulation precipitates during mixing with a volume of 1 ml of a test buffer solution Tp.Type: GrantFiled: May 5, 2008Date of Patent: August 7, 2012Assignee: Flamel TechnologiesInventors: Frédéric Checot, Cecile Bonnet-Gonnet, You-Ping Chan, Olivier Breyne, Remi Meyrueix
-
Publication number: 20120172220Abstract: The present invention provides N-phosphonomethylglycine guanidine salts. The N-phosphonomethylglycine guanidine salts have improved herbicidal efficacy over glyphosate alone. The present invention also provides guanidine compounds and salts thereof.Type: ApplicationFiled: June 24, 2010Publication date: July 5, 2012Applicants: FLAMEL TECHNOLOGIES S.A., MONSANTO TECHNOLOGY LLCInventors: Ronald J. Brinker, Olivier Soula, Alain Lemercier
-
Patent number: 8206744Abstract: The invention concerns novel materials based on biodegradable branched polyaminoacids particularly useful for transporting active principle(s). The invention also concerns novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on polyaminoacids. The invention aims at providing a novel polymeric material, capable of being used for transporting active principle(s) and enabling all the required relevant specifications to be optimally satisfied: biocompatibility, biodegradability, easy ability to be combined with a large number of active principles or to solubilize same, and to release the active principles in vivo. This is achieved by the present invention which firstly concerns branched polyaminoacids comprising aspartic acid units and or glutamic acid units, and which bear hydrophobic groups including 8 to 30 carbon atoms.Type: GrantFiled: July 19, 2005Date of Patent: June 26, 2012Assignee: Flamel TechnologiesInventors: Rémi Soula, Gauthier Pouliquen, You-Ping Chan